PuSH - Publikationsserver des Helmholtz Zentrums München

Müller, T.D. ; Blüher, M. ; Tschöp, M.H. ; DiMarchi, R.D.*

Anti-obesity drug discovery: Advances and challenges.

Nat. Rev. Drug Discov. 21, 201-223 (2022)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Glucagon-like Peptide-1; Diet-induced Obese; Growth-factor 21; Body-mass Index; Term Weight Control; Cardiovascular Risk-factors; Improves Glycemic Control; Semaglutide 2.4 Mg; Dependent Insulinotropic Polypeptide; Cannabinoid-1 Receptor Blocker
ISSN (print) / ISBN 1474-1776
Zeitschrift Nature Reviews - Drug Discovery
Quellenangaben Band: 21, Heft: 3, Seiten: 201-223 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Förderungen German Research Foundation
German Center for Diabetes Research (DZD e.V.)
European Research Council (ERC)
Alexander von Humboldt Foundation